Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News Clarity Pharmaceuticals begins Phase II SECuRE trial with first patient dosed using 67Cu-SAR-bisPSMA and enzalutamide Clarity Pharmaceuticals starts Phase II of SECuRE trial for prostate cancer, combining 67Cu-SAR-bisPSMA with enzalutamide in first treated patient. byPallavi MadhirajuApril 16, 2025